CPT code 83516 – Immunoassay for non-infectious analyte

Key takeaways

CPT code 83516 covers qualitative or semiquantitative immunoassay by a multiple step method, for non-infectious analytes.

CPT 83519 is quantitative by radioimmunoassay and 83520 is quantitative by any other method, so the result type and the method drive code selection.

Medicare covers 83516 under LCD L33261 for allergy testing. Weak ICD-10 specificity is the top denial trigger.

Pabau’s claims management software submits 83516 claims through Claim.MD and tracks every payer response in one queue.

CPT code 83516: official descriptor and code definition

The American Medical Association’s CPT code set defines 83516. The official descriptor reads: Immunoassay for analyte other than infectious agent antibody or antigen; qualitative or semiquantitative, multiple step method. Each clause in that descriptor narrows the code, so read all four before you assign it.

The code belongs to CPT’s Chemistry Procedures subsection within Pathology and Laboratory. It sits in the 83516-83520 family of immunoassay codes written for an analyte not otherwise specified. There is no CPT 83517. The codes beside 83516 are 83518, 83519 and 83520, and each one turns on the result type or the method.

What 83516 covers: eligible tests and clinical scenarios

CPT 83516 applies when the performing laboratory uses a multi-step method to detect a non-infectious analyte and reports the result qualitatively or semiquantitatively. The most common clinical scenarios billed under this code are:

• Allergen-specific IgE testing — ELISA-based panels measuring IgE antibodies to environmental or food allergens. Results come back as class scores (0-6) rather than precise IU/mL values. For Medicare patients these are governed by CMS LCD L33261.
• Autoimmune marker detection — antineutrophil cytoplasmic antibody (ANCA) immunofluorescence assays, and anti-nuclear antibody (ANA) screenings run by multi-step immunoassay methods.
• Hormone and biomarker screening — non-infectious analytes where a specific CPT code does not exist and the result is qualitative.
• Therapeutic drug monitoring (qualitative range) — where the analyte has no assigned specific code and the lab uses an ELISA-type method.

Mayo Clinic Laboratories lists CPT 83516 in its test catalog for several multi-step immunoassay panels, which shows how reference labs apply it. Confirm with the performing laboratory that no more specific CPT code exists before you select 83516.

What 83516 does not cover: exclusions and limitations

Because 83516 is a catchall code, its boundaries matter as much as what it covers. Use a more specific code whenever one exists for the analyte being tested.

• Infectious agent antibody or antigen immunoassays — tests for HIV antibody, hepatitis B surface antigen, COVID-19 antibody and similar markers belong in the 86xxx CPT range. They are never billed as 83516.
• Quantitative results — when the lab reports a precise numeric concentration, such as 45 IU/mL, 83516 no longer applies. Use 83519 for a quantitative result by radioimmunoassay (RIA). Use 83520 for a quantitative result by any other method.
• Single step methods — rapid point-of-care tests in a single step format do not meet the multiple step requirement. CPT 83518 covers that format instead.
• Analytes with their own CPT code — where the CPT codebook assigns a specific code to that analyte, 83516 is the wrong choice. The claim may also trigger an edit.

NOS codes like 83516 are misapplied most often when a more specific analyte code already exists. The lab report settles both the method and the result type, so read it before the code is assigned.

CPT 83516 vs 83519 vs 83520: how to choose the right code

These three codes are a common source of coding errors in laboratory billing. Two facts decide which one applies. The first is the type of result the laboratory reported. The second is the method it used to get there.

Start with the lab report. If the result is a class score, a titer, or positive/negative, and the method is multi-step, CPT code 83516 applies. If the result is a precise numeric value, the method decides between 83519 and 83520. The chart below runs the same two questions in order.

How the assay is performed and what the lab report must show

Not every immunoassay format meets the multiple step requirement. The lab report has to document the methodology explicitly for the claim to survive audit.

A typical multi-step immunoassay sequence proceeds as follows:

1. Sample preparation — serum or plasma is collected and separated from whole blood.
2. Coating or capture step — the microplate well or solid phase is coated with a capture antibody or antigen.
3. Incubation — the patient sample is incubated with the capture surface, and the target analyte binds if present.
4. Wash cycle — unbound material is removed in one or more wash steps.
5. Detection antibody incubation — a labeled secondary antibody is added, and another wash follows.
6. Signal detection — optical density or fluorescence is read, and the result is reported as qualitative or semiquantitative.

For the claim to be defensible, the lab report has to state four elements:

• The analyte name.
• The methodology, described as multi-step or ELISA-type.
• The result, reported as qualitative or semiquantitative.
• The clinical indication the test was ordered for.

Missing any one of them is enough for a payer reviewer to downcode or deny the claim. Build a lab-report check into the pre-billing review step so the omission is caught before submission.

Medical necessity and payer coverage policies

For Medicare patients, CPT code 83516 is governed mainly by CMS Local Coverage Determination L33261. That LCD covers allergy testing, including immunoassay-based allergen-specific IgE testing. Coverage is not automatic. The test must be ordered for a patient with a documented allergic condition, and the ordering physician’s notes have to support the specific analyte panel.

Payer coverage for 83516 varies considerably outside Medicare. These are the policy distinctions to verify with each payer before submission:

• Medicare (CLFS) — covered under LCD L33261 for allergy indications. Non-allergy NOS immunoassays may need individual consideration or an Advance Beneficiary Notice.
• Commercial payers — some carriers publish separate medical policies for specific analyte categories that name 83516 directly. Verify the policy number against the analyte being tested.
• Prior authorization — some payers require prior auth for NOS codes. Because 83516 names no analyte in its descriptor, it draws more scrutiny than codes that do.
• Frequency limits — LCD L33261 sets frequency restrictions for allergy testing panels. Exceeding them without documenting a clinical change triggers denial.

The same rule applies here as to any other laboratory test. The diagnosis code on the claim must match the clinical indication in the ordering note, rather than the most convenient code for the analyte category.

ICD-10 diagnosis codes commonly paired with 83516

ICD-10 codes paired with 83516 must reflect the clinical indication documented in the ordering note. Weak or generic ICD-10 pairing is the most common reason CPT code 83516 claims are denied on medical necessity grounds.

D89.9 is a high-denial pairing because payers read it as thin justification for an NOS immunoassay. Code to the highest specificity the documentation supports, and check the wording in the ICD-10-CM code set before the claim goes out.

2026 Medicare reimbursement rate and fee schedule

CPT code 83516 is reimbursed under the Medicare Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. The CLFS rate is set annually by CMS and applies nationally, though individual Medicare Administrative Contractors (MACs) may apply local coverage edits.

For current 2026 allowed amounts, use the CMS Clinical Laboratory Fee Schedule page and the annual rate table it publishes. CLFS rates are not built from RVUs, so an RVU lookup tool cannot answer this question. The files are updated each January 1.

Commercial payer rates typically exceed Medicare CLFS rates for laboratory codes. Some plans still use Medicare as their reference rate for NOS codes, so confirm contracted rates directly with each payer.

Two points shape what 83516 actually pays in 2026. The CLFS rate applies per test, per analyte, per date of service. If a panel of allergens runs in a single multi-analyte ELISA, read the laboratory’s methodology report. It decides whether multiple units of 83516 are reportable, or whether a panel code applies instead.

Top reasons 83516 claims are denied, and how to prevent them

The NOS designation invites payer scrutiny, so 83516 claims are reviewed more closely than codes that name their analyte. Each denial reason below pairs with an action billing staff can take before submission.

Pre-submission review earns its time on 83516, because the NOS status means no payer approves the claim on the code alone. Strong denial management workflows flag it for a second look before the batch goes out.

When to issue an Advance Beneficiary Notice

An Advance Beneficiary Notice (ABN) goes to the Medicare patient before the 83516 test is ordered. That applies whenever there is reason to believe Medicare will not cover the service. Without a signed ABN on file, the practice absorbs the cost if the claim is denied, and the patient cannot be billed.

Issue an ABN for 83516 when any of the following conditions apply:

1. The indication does not meet LCD L33261 criteria — the diagnosis or symptom pattern does not match the LCD’s covered indications for allergy testing.
2. The analyte is not on the payer’s covered list — the analyte being tested falls outside the covered analytes in the applicable LCD or coverage article.
3. Frequency limits have been reached — the patient has already had the maximum covered panels within the LCD’s frequency window. No clinical change is documented.
4. The ordering indication is investigational — the immunoassay is ordered for a use case not recognized as medically necessary under current coverage policy.

The ABN has to be delivered before the test is ordered, not after the denial. CMS Form CMS-R-131 is the required document format. Retain the signed original with the patient’s billing record. Store it in the same system as the lab order and the claim, so an audit finds all three.

Documentation checklist before you submit

Billing staff can run this checklist before submitting any CPT code 83516 claim. Each item addresses a known denial trigger identified in payer policy and coding guidance.

• Correct code selected — the lab report shows a qualitative or semiquantitative result and a multiple step method, which rules out 83518, 83519 and 83520.
• Methodology documented — the lab report explicitly states a multi-step method, such as ELISA or immunofluorescence.
• No more specific code exists — confirmed in the AMA CPT codebook that 83516 is the most specific applicable code for this analyte.
• ICD-10 code matches the clinical note — the diagnosis code is the most specific one the ordering provider’s documentation supports on the date of service.
• Prior auth obtained if required — the payer’s PA requirement is confirmed and the PA number is documented on the claim form.
• ABN on file where Medicare coverage is uncertain — a signed CMS-R-131 is retained with the billing record, dated before the test was ordered.
• Analyte name documented — the lab report and the claim record both state the analyte, because “immunoassay” alone is insufficient.
• Ordering provider’s NPI on the claim — required for Medicare CLFS claims, and a missing NPI triggers a technical denial.

Teams that run this check on every 83516 claim catch the two errors behind most of the rework. Those are a method mismatch and a diagnosis code that is too broad. Both are cheap to fix before submission and expensive to appeal afterwards.

How Pabau supports lab billing for 83516 claims

Most practices track lab claims in two places at once. The codes sit in the laboratory’s portal and the claim sits in the billing system. The methodology detail that supports 83516 then never travels with the claim, so the person writing the appeal starts by hunting for it.

Pabau is practice management software for medical and aesthetic practices, and it includes claims software for billers who handle laboratory codes. Claims are submitted electronically through Claim.MD, and every payer response comes back into the same queue. Billing staff see which 83516 claims were paid and which were denied, with the CARC reason code the payer returned.

The outcome is a shorter appeal cycle. When a denial arrives, the claim, the diagnosis code and the patient record are already in one place. Nobody has to rebuild the file before writing the appeal.

Submit and track lab claims in one place

Pabau submits your 83516 claims through Claim.MD and brings every payer response back into the same queue. Denials arrive with their CARC reason code, next to the patient record the claim came from.

Book a demo

Conclusion

Coding 83516 correctly is mostly a documentation habit. Read the methodology line and the result line on the lab report before the code is assigned, every time. A coder who does that rarely reaches for 83516 when 83518, 83519 or 83520 was the right answer.

The trade-off worth remembering is that an NOS code buys coverage breadth at the cost of scrutiny. Because the descriptor names no analyte, the ICD-10 pairing and the ordering note carry the whole medical necessity argument. Weak documentation costs more on 83516 than on a code that names its analyte.

Pabau’s claims tools submit these claims and track every payer response in one queue. Book a demo to see how lab billing runs end to end in a single system.

Continue your research

Need to understand how clearinghouse validation works for lab claims? Medical claims clearinghouse guide explains how payer-level edits catch code errors before submission.

Want to reduce denial rates across all claim types? Revenue cycle management fundamentals covers the pre-billing review steps that prevent 83516-style NOS denials.

Need to verify CPT codes against CMS eligibility before ordering? Insurance eligibility verification outlines the real-time check that confirms coverage status before a lab test is ordered.

Frequently asked questions